Understanding the Pathogenesis of Zika Virus Infection Using Animal Models
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Krause, Keeton K. | - |
dc.contributor.author | Azouz, Francine | - |
dc.contributor.author | Shin, Ok Sarah | - |
dc.contributor.author | Kumar, Mukesh | - |
dc.date.accessioned | 2021-09-03T00:55:12Z | - |
dc.date.available | 2021-09-03T00:55:12Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2017-10 | - |
dc.identifier.issn | 1598-2629 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/82112 | - |
dc.description.abstract | Zika virus (ZIKV) is a member of Flaviviridae family that has emerged as a pathogen of significant public health importance. The rapid expansion of ZIKV in the South and Central America has recently gained medical attention emphasizing the capacity of ZIKV to spread to non-endemic regions. ZIKV infection during pregnancy has been demonstrated to cause microcephaly and other fetal developmental abnormalities. An increased incidence of Guillain-Barre syndrome, an immune mediated neuropathy of the peripheral nervous system, has also been reported in ZIKV-infected patients in French Polynesia and Brazil. No effective therapies currently exist for treating patients infected with ZIKV. Despite the relatively short time interval, an intensive effort by the global scientific community has resulted in development of animal models to study multiple aspects of ZIKV biology. Several animal models have been established to investigate pathogenesis of ZIKV in adults, pregnant mothers, and developing fetuses. Here we review the remarkable progress of newly developed small and large animal models for understanding ZIKV pathogenesis. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREA ASSOC IMMUNOLOGISTS | - |
dc.subject | SEXUAL TRANSMISSION | - |
dc.subject | GUINEA-PIG | - |
dc.subject | ANTIVIRAL DRUG | - |
dc.subject | VIRAL DYNAMICS | - |
dc.subject | UNITED-STATES | - |
dc.subject | MOUSE MODEL | - |
dc.subject | EFFICACY | - |
dc.subject | BRAIN | - |
dc.subject | SOFOSBUVIR | - |
dc.subject | VACCINE | - |
dc.title | Understanding the Pathogenesis of Zika Virus Infection Using Animal Models | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Shin, Ok Sarah | - |
dc.identifier.doi | 10.4110/in.2017.17.5.287 | - |
dc.identifier.scopusid | 2-s2.0-85033230318 | - |
dc.identifier.wosid | 000418284200003 | - |
dc.identifier.bibliographicCitation | IMMUNE NETWORK, v.17, no.5, pp.287 - 297 | - |
dc.relation.isPartOf | IMMUNE NETWORK | - |
dc.citation.title | IMMUNE NETWORK | - |
dc.citation.volume | 17 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 287 | - |
dc.citation.endPage | 297 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART002278275 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.subject.keywordPlus | SEXUAL TRANSMISSION | - |
dc.subject.keywordPlus | GUINEA-PIG | - |
dc.subject.keywordPlus | ANTIVIRAL DRUG | - |
dc.subject.keywordPlus | VIRAL DYNAMICS | - |
dc.subject.keywordPlus | UNITED-STATES | - |
dc.subject.keywordPlus | MOUSE MODEL | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | BRAIN | - |
dc.subject.keywordPlus | SOFOSBUVIR | - |
dc.subject.keywordPlus | VACCINE | - |
dc.subject.keywordAuthor | Zika virus | - |
dc.subject.keywordAuthor | Animal model | - |
dc.subject.keywordAuthor | Etiology | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.